Association of Low-Dose Quetiapine and Diabetes | Zendy

Mikkel Højlund | Zendy; Lars Christian Lund | Zendy; Kjeld Andersen | Zendy; Christoph U. Correll | Zendy; Jesper Hallas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Low-Dose Quetiapine and Diabetes

Author(s) -

Mikkel Højlund,

Lars Christian Lund,

Kjeld Andersen,

Christoph U. Correll,

Jesper Hallas

Publication year - 2021

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2021.3209

Subject(s) - quetiapine , medicine , type 2 diabetes , incidence (geometry) , psychiatry , bipolar disorder , diabetes mellitus , schizophrenia (object oriented programming) , pediatrics , endocrinology , cognition , physics , optics

Key Points Question Is the use of quetiapine in low doses associated with increased risk of diabetes? Findings In this nationwide cohort study that included 57 701 new users of quetiapine in low doses and without severe mental illness, the incidence of diabetes was approximately 9 cases per 1000 person-years, similar to that of a reference population treated with selective serotonin reuptake inhibitors for other psychiatric disorders. Meaning Quetiapine used in low doses was not associated with an increased risk of diabetes among individuals with nonsevere mental illness in comparison with use of selective serotonin reuptake inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research